Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.54 |
| ▸ | MMP3 | P08254 | 1/20 | 0.54 |
| ▸ | MMP9 | P14780 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 4/20 | 0.51 |
| ▸ | CA1 | P00915 | 3/20 | 0.51 |
| ▸ | CTSK | P43235 | 2/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.42 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.42 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19456959 | 0.90 | MMP1 (0.53) | MMP1MMP3MMP9CA2CA1 | |
| SCHEMBL19456962 | 0.90 | MMP1 (0.53) | MMP1MMP3MMP9CA2CA1 | |
| SCHEMBL19784346 | 0.88 | SIRT2 (0.50) | MMP1MMP3MMP9SIRT5SIRT2 | |
| SCHEMBL18819662 | 0.86 | CA2 (0.51) | MMP1MMP3MMP9CA2CA1 | |
| SCHEMBL18831956 | 0.86 | CA2 (0.51) | MMP1MMP3MMP9CA2CA1 | |
| SCHEMBL19456956 | 0.86 | MMP1 (0.49) | MMP1MMP3MMP9CA2CA1 | |
| SCHEMBL19783967 | 0.84 | CA2 (0.51) | MMP1MMP3MMP9CA2CA1 | |
| SCHEMBL20282050 | 0.84 | CA2 (0.51) | MMP1MMP3MMP9CA2CA1 | |
| SCHEMBL23286132 | 0.83 | HDAC8 (0.52) | CTSKCTSSHDAC8HDAC4HDAC1 | |
| SCHEMBL16450329 | 0.83 | SMN1; SMN2 (0.46) | HDAC8SIRT5SIRT2SIRT1SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10683327-B2 | Compounds, linker-drugs and ligand-drug conjugates | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2020-06-16 | — | — | US | disclosed |
| US-10618935-B2 | Antibody-drug conjugate (ADC) and method for forming the same | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2020-04-14 | — | — | US | disclosed |
| US-20190106459-A1 | COMPOUNDS, LINKER-DRUGS AND LIGAND-DRUG CONJUGATES | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2019-04-11 | — | — | US | disclosed |
| US-10233212-B2 | Compounds, linker-drugs and ligand-drug conjugates | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2019-03-19 | — | — | US | disclosed |
| US-20180016300-A1 | COMPOUNDS, LINKER-DRUGS AND LIGAND-DRUG CONJUGATES | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2018-01-18 | — | — | US | disclosed |
| US-20170119902-A1 | ANTIBODY-DRUG CONJUGATE (ADC) AND METHOD FOR FORMING THE SAME | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2017-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016300-A1 | COMPOUNDS, LINKER-DRUGS AND LIGAND-DRUG CONJUGATES | SLC43A1, HCAR3, SLC7A1 | MMP1 1317/4885MMP3 865/4885MMP9 1633/4885 |
| US-10683327-B2 | Compounds, linker-drugs and ligand-drug conjugates | SLC43A1, HCAR3, SLC7A1 | MMP1 1317/4885MMP3 865/4885MMP9 1633/4885 |
| US-10233212-B2 | Compounds, linker-drugs and ligand-drug conjugates | SLC43A1, HCAR3, SLC7A1 | MMP1 1317/4885MMP3 865/4885MMP9 1633/4885 |
| US-20170119902-A1 | ANTIBODY-DRUG CONJUGATE (ADC) AND METHOD FOR FORMING THE SAME | DNPEP, DLST, DDOST | MMP1 1135/4885MMP3 1836/4885MMP9 1695/4885 |
| US-10618935-B2 | Antibody-drug conjugate (ADC) and method for forming the same | DNPEP, DLST, DDOST | MMP1 1135/4885MMP3 1836/4885MMP9 1695/4885 |
| US-20190106459-A1 | COMPOUNDS, LINKER-DRUGS AND LIGAND-DRUG CONJUGATES | SLC43A1, HCAR3, SLC7A1 | MMP1 1317/4885MMP3 865/4885MMP9 1633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.